GlobeNewswire 10/02/2021 Basilea reports positive topline results from phase 2 study FIDES-01 for derazantinib in FGFR2 gene ...
GlobeNewswire 09/02/2021 Continued strong Cresemba® (isavuconazole) sales trigger milestone from Pfizer to Basilea of USD 10 ...
GlobeNewswire 11/01/2021 Basilea reports preliminary 2020 revenue and portfolio progress
GlobeNewswire 07/01/2021 Basilea’s partner Asahi Kasei Pharma completes patient enrolment in phase 3 study with antifungal is...
GlobeNewswire 25/11/2020 Basilea reports acceptance for regulatory review of Pfizer’s marketing authorization application for...
GlobeNewswire 06/11/2020 Basilea announces approval of antibiotic Zevtera® in China to treat community-acquired pneumonia and...
GlobeNewswire 28/10/2020 Basilea announces Clinical Trial Collaboration and Supply Agreement with Eli Lilly and Company for r...
GlobeNewswire 26/10/2020 Basilea presents preclinical data on anti-angiogenic activity of derazantinib at ENA 2020
GlobeNewswire 13/10/2020 Basilea reports interim results from phase 1/2 study FIDES-02 exploring derazantinib in patients wit...
GlobeNewswire 12/10/2020 Basilea reports pooled efficacy data for derazantinib in iCCA patients with FGFR2 gene mutations and...
GlobeNewswire 29/09/2020 Basilea initiates targeted biomarker-driven phase 2 study with lisavanbulin in patients with brain c...
GlobeNewswire 28/09/2020 Basilea starts phase 1/2 study FIDES-03 with derazantinib in patients with gastric cancer
GlobeNewswire 22/09/2020 Basilea reports data from poster presentations at ESMO Virtual Congress 2020
GlobeNewswire 11/08/2020 Basilea reports strong financial results for half-year 2020, progress in R&D portfolio and successfu...
GlobeNewswire 07/08/2020 Basilea reports acceptance for regulatory review of Pfizer’s marketing authorization application for...
GlobeNewswire 28/07/2020 Basilea announces data presentations at ESMO Virtual Congress 2020
GlobeNewswire 20/07/2020 Basilea announces completion of patient enrolment into first cohort of phase 2 study FIDES-01 with d...
GlobeNewswire 15/07/2020 Basilea reports the launch of antifungal Cresemba® (isavuconazole) in Taiwan, triggering the second ...
GlobeNewswire 30/06/2020 Basilea announces move of corporate headquarters to Allschwil, canton of Basel-Landschaft, in 2022
GlobeNewswire 23/06/2020 Basilea enters into sale and leaseback agreement for corporate headquarters building
GlobeNewswire 22/06/2020 Basilea receives CHF 5 million milestone payment related to marketing authorization of antifungal Cr...
GlobeNewswire 28/05/2020 Basilea provides corporate update
GlobeNewswire 29/04/2020 Basilea announces appointment of new Head of Global Quality Management
GlobeNewswire 08/04/2020 Basilea shareholders approve all proposals of the Board of Directors at the Annual General Meeting
GlobeNewswire 27/02/2020 Basilea reports the launch of antifungal Cresemba® (isavuconazole) in Australia triggering the first...